Servier agreed to acquire Edgewise Therapeutics’ muscular dystrophy business for $1.55 billion upfront, with total consideration up to $2.65 billion including potential milestones. The deal gives the French pharma access to sevasemten, an oral therapy designed to protect muscle from ongoing damage in neuromuscular disorders. Sevasemten is in a pivotal trial in Becker muscular dystrophy and a Phase 2 study in Duchenne muscular dystrophy. Servier said the program could generate pivotal data by year’s end, positioning the asset as a near-term catalyst for the neurology pipeline. The transaction underscores how large-cap pharma continues to consolidate late-stage neuromuscular opportunities to accelerate decision-making and de-risk development timelines.